| Bid | 67.22 |
| Market Cap | 3.27B |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | 3.95 |
| PE Ratio (ttm) | 17.56 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 71.88 |
| Volume | 407,550 |
| Avg. Volume (20D) | 434,221 |
| Open | 69.52 |
| Previous Close | 69.03 |
| Day's Range | 68.74 - 70.02 |
| 52-Week Range | 68.15 - 102.50 |
| Beta | undefined |
About ASH
Ashland Inc. provides additives and specialty ingredients worldwide. It operates through Life Sciences; Personal Care & Household; Specialty Additives; and Intermediates and Solvents segments. The Life Sciences segment offers pharmaceutical solutions, including controlled release polymers, disintegrants, tablet coatings, thickeners, solubilizers, and tablet binders; nutrition solutions, such as thickeners, stabilizers, emulsifiers, and additives;...
Analyst Forecast
According to 7 analyst ratings, the average rating for ASH stock is "Buy." The 12-month stock price forecast is $98.5, which is an increase of 41.97% from the latest price.
Next Earnings Release
Analysts project revenue of $436.27M, reflecting a -7.77% YoY shrinking and earnings per share of 0.64, making a 42.22% increase YoY.
1 month ago · seekingalpha.com
Ashland: A Stable Stock Trading At 50% Discount To Its Intrinsic ValueAshland Inc. (NYSE: ASH) offers a promising upside of 58.3% with a target price of $125.72, driven by its strong financial fundamentals and growth potential in biotechnology. The company is well-diver...
1 month ago · businesswire.com
Innate Pharma Highlights Abstracts Selected for the ASH Annual Meeting 2024MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that abstracts related to lacutamab healt...
